Janssen Biotech, Inc.
10 drugs in NADAC|0 Generic,10 Brand
Janssen Biotech, Inc. lists 10 NDCs in the CMS NADAC file (0 generic, 10 brand), at an average NADAC of $13099.89 per unit, with a week-over-week move of -0.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
10
0G / 10B
Avg Price / Unit
$13099.8878
$87.63 – $29874.45
Avg 7d Change
-0.04%
Across 3 drugs with changes
7d Activity
of 10 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
golimumab market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Interleukin-23 Antagonist therapeutic class
Review the broader class where Janssen Biotech, Inc. has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Janssen Biotech, Inc. make?
Janssen Biotech, Inc. lists 10 NDCs in the CMS NADAC file — 0 generic and 10 brand products.
What is the average price of Janssen Biotech, Inc. drugs?
The average NADAC across Janssen Biotech, Inc.'s portfolio is $13099.8878 per unit, ranging from $87.6254 to $29874.4480.
What types of drugs does Janssen Biotech, Inc. make?
Janssen Biotech, Inc. makes drugs across 4 FDA pharmacologic classes. The most common by NDC count are Interleukin-23 Antagonist (5), Tumor Necrosis Factor Blocker (4), Interleukin-12 Antagonist (2), Cytochrome P450 17A1 Inhibitor (1).
Has Janssen Biotech, Inc. had any drug recalls?
No FDA enforcement recalls are matched to Janssen Biotech, Inc. in the openFDA feed.
How has Janssen Biotech, Inc.'s pricing changed recently?
Over the past 7 days, 1 Janssen Biotech, Inc. product rose and 2 fell, with a portfolio-wide average change of -0.0%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
STELARA 45 MG/0.5 ML SYRINGE ustekinumab | $29874.4480 per ML | — |
STELARA 90 MG/ML SYRINGE ustekinumab | $29792.7867 per ML | — |
TREMFYA 100 MG/ML ONE-PRESS Guselkumab | $14743.7181 per ML | -0.01% |
TREMFYA 100 MG/ML SYRINGE Guselkumab | $14728.9053 per ML | — |
SIMPONI 50 MG/0.5 ML SYRINGE golimumab | $12977.2440 per ML | — |
SIMPONI 50 MG/0.5 ML PEN INJEC golimumab | $12890.3164 per ML | -0.15% |
SIMPONI 100 MG/ML PEN INJECTOR golimumab | $7446.2126 per ML | — |
TREMFYA 200 MG/2 ML PEN guselkumab | $7321.6557 per ML | +0.04% |
REMICADE 100 MG VIAL INFLIXIMAB | $1135.9660 per EA | — |
ZYTIGA 250 MG TABLET abiraterone acetate | $87.6254 per EA | — |